EMT inhibitor-1 (C007B-353271)

EMT inhibitor-1 is an inhibitor of of Hippo , TGF-β , and Wnt signaling pathways with antitumor activities.In VitroEMT inhibitor-1 (C19) (0-10μM; 24 hours) is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities, inhibiting cancer cell migration, proliferation, and resistance to doxorubicin in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoEMT inhibitor-1 (C19) (intraperitoneal injection; 5-20 mg/kg) exerts strong antitumor activity in a mouse tumor model. Mechanistically, EMT inhibitor-1 induces GSK3-β–mediated degradation of the Hippo transducer TAZ, through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK upstream of the degradation complex .C19 is dissolved in the vehicle solution (100 μL of DMEM containing 5% dimethyl sulfoxide). MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Hippo, TGF-β, Wnt.

Specifications and Purity: ≥99%

Molecular Formula: C12H12Cl2N2O2S

Molecular Weight: 319.21

PubChem CID: 90718214

Isomeric SMILES: C1=CC(=C(C=C1C2=NSN=C2OCCCCO)Cl)Cl